On 2 July, Alector and GlaxoSmithKline (GSK) have announced a strategic global collaboration for the development and commercialisation of two therapies for neurogenerative diseases. Both investigational therapies using antibodies (AL001 and AL101) are designed to elevate the levels of progranulin in the body, which is a key regulator of immune activity in the brain.
A Phase III study evaluating the efficacy and safety of AL001 in people at risk for or with frontotemporal dementia due to a progranulin gene mutation is currently underway in US, Australia and Europe. A Phase II study is investigating the safety and efficacy of AL001 in participants at risk for or with frontotemporal dementia due to mutations in the progranulin or C9orf72 genes (a mutation in one of these genes is a major genetic cause of frontotemporal dementia). AL001 is currently underway in a Phase I clinical trial with healthy volunteers and is intended to be developed for treatment of Parkinson’s disease and Alzheimer’s disease. Under the terms of the collaboration agreement, Alector will receive USD 700 million in upfront payments. Alector will also be eligible to receive up to an additional USD 1.5 billion in clinical development, regulatory and commercial launch-related milestone payments.
https://www.gsk.com/en-gb/media/press-releases/gsk-and-alector-collaboration-in-immuno-neurology/
